CVR - Coronavirus Vaccines R&D Roadmap

Milestone
5.1.b

Communication tools

In progress

Develop targeted advocacy strategies and communication tools for governments, multilateral organizations, developers, funders, and the general population to provide information on the health, societal, and economic costs of future coronavirus threats, and potential benefits of vaccines, to foster continued investment in R&D and demand for coronavirus vaccines.

Progress Highlights

CEPI launched the “Viral Most Wanted” series in 2025, which highlights the viral families posing the greatest risk to humanity; coronaviruses are one of seven priority viral families.

CEPI has advanced its “100 Days Mission” as a flagship advocacy initiative to accelerate vaccine development timelines for emerging pathogens, helping shape global policy discussions and mobilize political and financial support for pandemic preparedness.

Gavi has developed a communications toolkit to support its replenishment efforts, providing messaging and materials to engage governments, donors, and the public on the value of sustained investment in immunization and pandemic preparedness.

The World Health Organization has developed public-facing communications and multimedia resources on the Pandemic Agreement to support awareness, stakeholder engagement, and political support for global pandemic preparedness efforts.

Resources for the CEPI 3.0 Investment Case include a toolkit with messaging frameworks, data visualizations, and communications materials designed to help partners, governments, and stakeholders advocate for sustained investment in epidemic and pandemic vaccine R&D. 

Through global forums and the media, CEPI has advanced its 100 Days Mission as a global goal for pandemic preparedness and response, and secured global political commitments (e.g., at G7 summits) for vaccine development against coronaviruses and other priority pathogens.

The WHO Pandemic Agreement was adopted in 2025, representing a major global political commitment to strengthen pandemic prevention, preparedness, and response, including provisions related to equitable access to vaccines and other medical countermeasures.

The Global Pandemic Preparedness Summit was convened in Rio de Janeiro, Brazil, in 2024 by CEPI, the Brazil Ministry of Health, Fundação Oswaldo Cruz, with WHO, the International Pandemic Preparedness Secretariat (IPPS), Unitaid, and other global stakeholders, to strengthen global commitment to accelerate R&D for vaccines and other countermeasures against coronaviruses and other priority pathogens, that would be available for rapid and equitable deployment. 

The Global Preparedness Monitoring Board in 2023 called for a pandemic preparedness advocacy movement that spans sectors, aligning pandemic prevention with other global priorities. The strategy entails inclusion of civil society, academia, industry, and community voices in a common platform. 

The WHO interim Medical Countermeasures Network (i-MCM-Net) was established in 2023 as a global “network of networks” and a coordination platform linking R&D, manufacturing, procurement, and access. It has been operationalized through mechanisms such as the mpox Access and Allocation Mechanism and ongoing partner convenings. Recent activities include discussions on pooled procurement of emergency medical countermeasures, alongside analytical work (e.g., stockpiling and simulation exercises) to inform equitable access and deployment strategies, including for priority pathogens such as coronaviruses.

  • WHO 2024: Defining access to countermeasures: landscape report: This landscape analysis maps the end-to-end medical countermeasures ecosystem, spanning R&D, manufacturing, allocation, and delivery, and identifies structural barriers to equitable access across pathogens, including current and novel coronaviruses as part of its case study.